Tagged with Roundup,

Roundup In recent pharma news from around Latin America, countries are beginning to manufacture their own tests and equipment for dealing with the COVID-19 pandemic so as to reduce dependence on outside sources. Moreover, as vaccines begin being developed globally, pharma firms are looking to Latin America to test their efficacy.…

Roundup A roundup of the latest news from Chinese biotechs, including a bumper IPO for Legend Biotech, a USD two million tie-up between Roche and Innovent Biologics, and a new Alphamab-Sanofi collaboration on KN026 in HER2+ Breast Cancer.   Fresh off ASCO myeloma data, Legend Bio gets USD 424 million in…

China A roundup of some of the top stories in China’s healthcare and life sciences industry, including challenges for Chinese biotechs in the post-pandemic era, why the country needs a biosecurity law, and Chinese companies’ vital role in manufacturing vaccine-related products.   Why does China need a biosecurity law? https://news.cgtn.com/news/2020-05-27/Why-does-China-need-a-biosecurity-law–QQ3wbQcxTG/index.html China…

Roundup A roundup of the latest news in Chinese pharma, including a US IPO for Burning Rock Biotech, positive news on CanSino’s COVID-19 vaccine trials, and WuXi Biologics’s first US facility.   Pandemic Exposes Perils of Global Reliance on China for Drug Supplies https://www.voanews.com/science-health/pandemic-exposes-perils-global-reliance-china-drug-supplies The spread of COVID-19 and the unprecedented…

Roundup Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access developments.   Coronavirus leading to ICU drug shortages In the UK the coronavirus pandemic is leading to shortages of drugs…

China Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi’s out-licensing of a potential COVID-19 treatment to Lilly, and Ascentage being granted US FDA orphan drug status for its leukaemia candidate.   Hong Kong IPOs Pick Up the Pace as China Restarts https://www.bloombergquint.com/onweb/hong-kong-ipos-pick-up-the-pace-as-china-restarts-ecm-watch Initial public…

China A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals.   In Q1 2020, China’s regulator the National Medical Products Administration (NMPA) approved a total of 11 new drugs, 6 imported and 5 domestic Made with Visme…

Brazil Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates.    Proposal to allow breaking of patents due to Covid-19 A proposal has been made to amend an intellectual property law, adding a clause on allowing compulsory licenses and breaking…

Russia Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association and new breakthroughs in Coronavirus diagnostics.   Government amends legislation around emergency response to diseases The State Duma, as is…

Germany Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital Healthcare Act, the impact of the coronavirus outbreak on investor sentiment, and the health minister potentially poised to become Germany’s…

Mexico Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program, cancer research, and the lack of coronavirus expertise in Mexico.   Zero tolerance for corruption: the Mexican pharma sector must…

India Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters to Indian pharma manufacturers, promising export markets, and the growth of the Indian domestic market.   Repurposing HIV drugs to…